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Abstract
Background. The purpose of the study was to measure clinical quality by doing an audit of clinical 
records and to compare the performance based on clinical quality indicators (CQI) for hypertension 
and type 2 diabetes across seven European countries: Estonia, Finland, Germany, Hungary, Italy, 
Lithuania and Spain.
Methods. Two common chronic conditions in primary care (PC), hypertension and type 2 diabetes, 
were selected for audit. The assessment of CQI started with a literature review of different databases: 
Organization for Economic Co-operation and Development, World Health Organization, European 
Commission European Community Health Indicators, US National Library of Medicine. Data were 
collected from clinical records.
Results. Although it was agreed to obtain the clinical indicators in a similar way from each country, 
the specific data collection process in every country varied greatly, due to different traditions in 
collecting and keeping the patients’ data, as well as differences in regulation regarding access to 
clinical information. Also, there was a huge variability across countries in the level of compliance 
with the indicators.
Conclusions. Measurement of clinical performance in PC by audit is methodologically challenging: 
different databases provide different information, indicators of quality of care have insufficient 
scientific proof and there are country-specific regulations. There are large differences not only in 
quality of health care across Europe but also in how it is measured.
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Introduction
Medical records (MR) contain a huge amount of routinely collected 
clinical data. This information can be used also to measure differ-
ent aspects of quality of health care. There is no doubt that qual-
ity of health care is important. However, assessment of it is often 
complicated. There are valid instruments for assessing the quality of 
practice management and a large amount of guidelines describing 
evidence-based treatment recommendations (1,2). Moreover, differ-
ent countries use varying lists of clinical quality indicators (CQI) 
to assess the quality of primary care (PC) (3–6). Topics for clinical 
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process measures are generally defined by conditions [e.g. high blood 
pressure, type 2 diabetes mellitus (T2DM)], although these may be 
identified for different age groups, settings or events. One well-
known set of indicators is the Quality and Outcomes Framework 
(QOF) in UK, which uses process measures to assess the perfor-
mance of PC (7). QOF is a voluntary process for all practices in the 
UK and awards achievement points for four domains: clinical care, 
organizational, patient experience and additional services domain. 
The clinical care domain of QOF includes 87 indicators across dif-
ferent clinical areas and performance of the clinical targets is used 
to calculate the financial incentives. A similar set of indicators is also 
found in other countries, e.g. in Canada (8).
Extracting information from MR could provide very detailed 
clinical data about common disorders in PC but is a complex, costly 
and time-consuming exercise. However, quality of health care is 
essential and we should be able to use feasible and objective assess-
ments. To the best of our knowledge, there is no evidence available 
about what set of CQI derived directly from MR is best for compari-
sons across countries or different PC systems.
The aim of the study was to measure clinical quality by doing 
an audit of MRs and to compare the performance based on CQI for 
hypertension and T2DM across European countries.
Methods
This study is part of the project ‘EUprimecare’, the objectives of 
which were to develop a framework aiming to analyse PC across 
Europe; to assess and compare PC models in terms of quality and 
identifying costs and to provide recommendations for PC services 
regarding quality and cost. There were seven countries participating 
in the project ‘EUprimecare’: Estonia, Finland, Germany, Hungary, 
Italy, Lithuania and Spain (9).
In this article we analyse one of the aims of the project, the 
assessment of the clinical quality.
The process of assessing a set of CQI
The assessment of the CQI started with the literature review. The 
objective was to identify those indicators, which will allow iden-
tifying differences between PC models in terms of clinical perfor-
mance. Initially, the Organization for Economic Co-operation and 
Development (OECD), World Health Organization (WHO) and 
European Commission European Community Health Indicators 
(ECHI) databases were searched to identify CQI (10–12). An ini-
tial list of indicators was identified, describing performance in the 
field of public health, screening, immunization and management of 
chronic diseases, and specific tasks of the PC providers.
The next step was to conduct a search of the literature to sup-
port the selection of CQI which can identify differences of quality in 
terms of clinical performance between PC models and which can be 
derived from MR. The following search strategy was used in order to 
identify systematic reviews in the US National Library of Medicine 
(PubMed) database: [(‘quality of health care’[MeSH Terms] AND 
‘primary health care’[MeSH Terms]) AND ‘clinical audit’[MeSH 
Terms]] AND systematic[sb].
Altogether 48 systematic reviews were found. None of them 
directly addressed the question about applicable CQI derived from 
MR for comparison of quality of PC between countries. There 
were different sets of indicators, mostly country specific and none 
of them directly applicable in at least two countries participating in 
EUprimecare project (3–6). The lack of an international agreed on 
list of indicators, promoted the necessity to develop a novel set of 
CQI for audit within the EUprimecare project. The starting point for 
the selection of the CQI was the list of CQI developed by the OECD 
(10). Two common chronic conditions, hypertension and T2DM, were 
selected for audit. These conditions were selected due to their high 
prevalence, lower control than needed, the high morbidity and mortal-
ity associated with them and the existence of accepted guidelines for 
the management at PC level (13–16). The precondition for including 
an indicator into the final set was the direct availability of the values of 
the indicator from MR for the majority of the participating countries 
in the EUprimecare project. If the values were not directly available 
for at least four participating countries, it was not included in the list. 
The final list of CQI was developed by consensus among the partners.
Data extraction from MR
Data were collected according to the project criteria and possibilities 
of each participating country.
Each country asked for permission from their local ethics com-
mittee to study the clinical data from patients’ records. The data 
collected related only to the objectives of the audit. Staff as well as 
patient confidentiality was respected.
We used stratified sampling and the number of PC centres allo-
cated from each country was predetermined by sample size calcula-
tions. All MR were assessed based on data from 2011 (all entries in 
2011 were included) and relevant clinical data were recorded using 
a uniform template. We included all patients with a diagnosis of 
T2DM (diagnoses E11 and E11.0–E11.9 according to the ICD-10 
classification), patients with diagnosis of hypertension (diagnoses 
I10, I11, I12, I13 according to the ICD-10 classification) or patients 
with both T2DM and hypertension.
Process of obtaining CQI from MR varied between partners. 
Therefore, we report it per country.
Estonia
We used the Estonian Health Insurance Fund database and invited all 
GP (N = 804) to participate in the study; 241 (30%) of them agreed. 
Then an employee of the Health Insurance Fund randomly selected 
two patients with T2DM and hypertension from the physician’s list 
of patients. The data of selected patients were forwarded to their 
physicians, who prepared coded and unidentified patient records and 
sent them to the investigators. In total, 562 cases were analysed, while 
45% of patients had both hypertension and T2DM, 10% of patients 
had only T2DM and 44% had only hypertension. Analysis was per-
formed on 247 patients with hypertension and 309 with T2DM.
Finland
Most of the PC in Finland is provided by municipal health cen-
tres. As the plan was to manually search electronic MR, only those 
health centres using two of the most common software systems were 
approached, which cover ~87% of the whole population. For prac-
tical travel cost-related purposes, the northernmost very sparsely 
populated region of Lapland was excluded. Out of the eligible 
municipalities, 37 were included in the sample after stratification 
by macro region and size of the health centre catchment popula-
tion. The sample was set to consist of ~1000 patients with T2DM 
and 2000 with hypertension. The National Pension Institute is the 
keeper of the registers of those with special entitlements. It extracted 
random lists of names and social security numbers for individuals. 
Out of these lists, individuals with codes for diabetes and hyperten-
sion were chosen, up to the target figure set for each municipality. 
In total, 25 centres from the 37 municipalities were approached for 
their permission to access the data. All agreed, but two were so late 
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in their reply that they had to be excluded. In order to compensate 
for the numbers of individuals lost, target numbers in municipalities 
in similar regions and communities were increased.
Germany
We used data from the Disease Management Programme (DMP) for 
T2DM from the North Rhine region. DMP constitute a population-
based integrated approach to care management, i.e. it covers the sec-
ondary and ambulatory care.
Hungary
The source of data was the Healthcare Episode Database operated 
by GYEMSZI IRF (Directorate General of Informatics and Health 
System Analysis). The Healthcare Episode Database processes the 
data of the National Health Insurance Fund.
Italy
Italian GPs do not use ICD-10 coding. Therefore, no data about 
patient care with T2DM and hypertension at the individual care 
cannot be collected.
Lithuania
The study was performed in Kaunas region, which is the most cen-
tral part of Lithuania, covering urban and rural areas. The economic 
indicators in this region are equal to the Lithuanian average. There 
are 49 PC centres in Kaunas region, which provide PC services 
under the contract with Sickness Funds. In Lithuania, the majority 
of centres use records in paper form and only one centre had insti-
tutional list about the patients with T2DM and hypertension, while 
in the other PC centres this information was provided personally by 
each physician. All patients of the same centre were merged and the 
needed numbers of patients were randomly selected for the audit. As 
the majority of T2DM patients had both diagnoses (hypertension 
and diabetes), the final number of patients with hypertension was 
higher than selected. As in one small urban and one medium urban 
centre the necessary number of patients with T2DM was not avail-
able, two additional centres (which represented the same size and 
urbanization) were included in the study.
Spain
The information of the study has been provided by the Healthcare 
Regional Service of Castilla y León. Depending on the indicator, the 
information was extracted from two different sources. Each source 
of information represents a specific population. There were a total of 
32 of those centres, which were distributed as follows: (i) two rural 
centres in Avila, (ii) two rural centres in Soria, (iii) two rural centres 
plus one urban health care centre in Valladolid and (iv) all rural and 
urban centres in Burgos.
For all the other indicators, PC centres with electronic MR have 
been selected, which represented ~80% of the Castilla y León popula-
tion. Electronic MR are implemented in the main PC centres as well 
as in offices located in towns with a population of 300–500 people.
Results
The final list of CQI is presented in Table 1. The indicators describe 
the proportion of patients with T2DM and/or hypertension screened 
for different factors (e.g. cholesterol, blood pressure).
Table  2 presents the results of the assessment of CQI in each 
country during 1 year. It was not possible to review MR in Italy and 
Germany due to data protection reasons; in Hungary, it was not pos-
sible to separate PC data from secondary care data. Therefore, we 
report data only about four countries: Estonia, Finland, Lithuania 
and Spain.
The proportion of hypertensive patients with a blood pressure 
level at or below goal (<140/90 mmHg) ranged between 33% and 
53% in different countries. Similarly, the proportion of hypertensive 
patients for whom the lipid profile was measured ranged between 
24% and 67%, being the lowest in Lithuania and Spain and the 
highest in Estonia.
Concerning T2DM, the proportions of patients with diabetes 
having an average blood pressure at or below goal (<130/80 mmHg) 
ranged between 8% and 62%. The lipid profile was measured in 
23–69% of patients with T2DM. The proportion of patients with 
diabetes with total cholesterol at or >4.5 mmol/l and statin treat-
ment provided ranged between 15% and 63% and the proportion 
of patients with T2DM with total cholesterol <4.5  mmol/l was 
20–54%. Glycated haemoglobin (HbA1c) was screened for 57–90% 
of patients with T2DM. The proportion of patients with T2DM with 
HbA1c <7% was between 49% and 67%. Similarly, the proportion 
of patients with diabetes with HbA1c ≥7–8.5% under insulin treat-
ment was 43–49%. The proportion of patients with T2DM having 
an eye examination ranged between 1% and 46%, being the lowest 
in Spain and the highest in Lithuania.
Most countries used electronic MR, except in Lithuania paper-
based MR are used. During the audit we also noticed that there were 
different ways of recording blood pressure readings for patients who 
monitor their blood pressure at home. In most cases, the typical 
record entered into the MR was a generalization, e.g. on the aver-
age, or usually on the acceptable levels, or usually <90, or similar. 
In other words, if the patient has a written card of the readings, 
the readings are not copied as such, but the doctor or nurse writes 
a summary or makes conclusion. In such cases the monitoring of 
blood pressure may look irregular, although it could be very regular 
in reality.
Discussion
The aim of the study was to measure clinical quality by doing an 
audit of MRs and to compare the performance based on CQI across 
different countries.
The first finding is the absence of a previously validated list of 
CQI. Although different organizations have proposed instruments 
to measure the quality of PC there is no consensus on how to use the 
information from MR for this assessment.
As a first step, indicators were agreed for two common chronic 
conditions in PC, hypertension and T2DM. Although it was required 
to obtain the CQI in a similar way from each country at the begin-
ning of the study, the specific data collection process in each country 
varied greatly, due to different traditions in collecting and keeping 
patients’ data, as well as differences in regulation regarding access to 
clinical information. This is a significant second finding. For exam-
ple, some countries were not able to collect data at individual patient 
level (Hungary, Germany, Italy) and in some countries not all pro-
posed indicators were collected. In most of the countries electronic 
MR were analysed (except Lithuania) and the data were collected in 
one region of the country. However, in Estonia, data were collected 
across the whole country and in Finland only the most northern part 
of the country was excluded due to practical reasons.
The third finding is the variability across countries in the level 
of compliance with the indicators. Concerning hypertension, the 
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proportion of hypertensive patients with a blood pressure level at 
or below goal ranged between 33% and 53% and the proportion 
of patients with diabetes having average blood pressure at or below 
goal ranged between 8% and 62% across countries.
One source of variation between countries arises from differences 
in national recommendations (in comparison to the international 
standards used to establish the indicator). For example, in Lithuania, 
according to the Health Ministry Order regarding T2DM care, phy-
sicians have to refer patients once a year for an eye fundus checkup, 
which this explains the highest activity between other countries. In 
the other words, high activity in the performance of some tests may 
be explained by country-specific regulations which unfortunately 
may not always correlate with the good treatment quality results. 
The other source of variation between results comes from the usual 
practice doctor–patient based variation, which is the usual focus of 
attention in comparisons of quality.
Trying to make comparisons of management of T2DM, which 
is called the epidemic of the 21st century, is complicated. For exam-
ple, in 2005 the European Core Indicators in Diabetes project 
report described the process of collecting data about diabetes (17). 
Nineteen European countries participated, but for most of the coun-
tries national data were not available. The indicators were derived 
from different sources and databases, and primary and secondary 
care provision were not separable. Also, type 1 diabetes patients 
were involved in the study. Therefore, these data cannot be used for 
comparison of diabetes care provision for countries participating in 
our project. Also, the WHO provides data for most of the countries. 
However, data from Lithuania and Estonia are incomplete.
Kilpeläinen et  al. (18) showed that the availability score for 
ECHI indicators was 74%, ranging from 56% to 84%. However, 
important indicators such as health provision, use of health care ser-
vices and the quality of health care and health care promotion are 
often missing. Quality of health care, according to ECHI indicators, 
is defined by survival rates for cancer, surgical wounds infections, 
equality of access to health care services, diabetes control, cancer 
treatment delay and waiting time for elective surgeries (19). Criticism 
of ECHI, WHO and OECD has been discussed and the conclu-
sion was that collaboration is needed between the WHO Europe, 
the OECD and the European Commission in the work towards an 
integrated European health information system (20). To sum up, 
there are large amounts of data and reports of routinely collected 
data available but the information is often scattered, fragmented, 
underutilized, incomparable and undervalued. Moreover, the data 
collection method is also important. According to Green et al. (21), 
the decision about which data collection method is best needs care-
ful consideration regarding its influence on the results. However, the 
medical chart audit is the most accurate method of data collection.
Strengths and limitations
The most important strength of this study is methodological—we 
analysed MR in a similar way across countries. Collecting data 
from MR is laborious and time-consuming. However, this is one 
of the most accurate methods for measuring actual performance. 
Limitation of our study is also that some samples were national, 
some regional, as well as participating GPs were not recruited in the 
same way in each country, which influences generalizability of our 
results. During the audit we noticed that needed data were often 
poorly found/not recorded systematically in MR. In the Canadian 
Quality Book of Tools there is a special indicator for MR keeping. 
Criteria for this indicator are that each patient record has to have 
Table 1. CQI for medical audit agreed by EUprimecare countries
Indicator Estimate Source of evidence
Proportion of patients with T2DM screened 
for HbA1c
Number of patients aged 25–75 years with confirmed T2DM with at least 
one HbA1c measurement done during 1 year/total number of patients aged 
25–75 with T2DM during 1 year
OECD, ADA/EASD
Proportion of patients with T2DM with HbA1c 
<7%
Number of T2DM patients aged 25–75 years with HbA1c value <7% dur-
ing 1 year/total number of patients aged 25–75 with T2DM during 1 year
OECD, ADA/EASD
Proportion of patients with T2DM screened for 
total cholesterol level
Number of T2DM patients aged 25–75 years with at least one cholesterol 
measurement during 1 year/total number of patients aged 25–75 with 
T2DM during 1 year
OECD, ESC
Proportion of patients with T2DM with total 
cholesterol <4.5 mmol/l
Number of T2DM patients aged 25–75 years with at total cholesterol value 
<4.5 mmol/l during 1 year/total number of patients aged 25–75 with T2DM 
during 1 year
OECD, ESC
Proportion of patients with T2DM with total 
cholesterol >4.5 mmol/l and statin treatment 
provided
Number of T2DM patients aged 25–75 years with total cholesterol at or 
>4.5 mmol/l and statin treatment provided/total number of patients aged 
25–75 with T2DM during 1 year
OECD, ESC
Proportion of patients with T2DM having aver-
age blood pressure <130/80 mmHg
Number of patients with T2DM having average blood pressure 
<130/80 mmHg according to the last measurement during 1 year/total  
number of patients aged 25–75 with T2DM during 1 year
OECD, ESC
Proportion of patients with T2DM having eye 
examination (fundus photography or ophthal-
mologist consultation recorded)
Number of T2DM patients aged 25–75 years having eye examination during 
1 year/total number of patients aged 25–75 with T2DM during 1 year
OECD, NICE
Proportion of patients with hypertension with 
blood pressure <140/90 mmHg
Number of patients aged 25–75 years with hypertension with blood  
pressure <140/80 mmHg according to the last measurement during 1 year/
total number of patients aged 25–75 with hypertension during 1 year
ESC, WHO/ISH
Proportion of patients with hypertension with 
total cholesterol screened within a year
Number of patients aged 25–75 years with hypertension with blood  
pressure <140/80 mmHg according to the last measurement during 1 year/
total number of patients aged 25–75 with hypertension during 1 year
OECD/ESC
ADA, American Diabetes Association; EASD, European Association for the Study of Diabetes; ESC, European Society of Cardiology; ISH, International Society 
of Hypertension; NICE, National Institute for Health and Care Excellence.
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a cumulative patient profile which includes up-to-date list of prob-
lems, medications, drug allergies and adverse drug reactions, a list 
of laboratory test results and of other examinations (8). Having a 
cumulative patient profile makes the data collection from MR easier.
Conclusions
In conclusion, the assessment of a set of CQI for measurement of 
clinical performance in PC is methodologically challenging because 
different databases provide information on different countries, which 
seriously limits the possibility to make direct cross-country compari-
sons. Applicability of this developed set of indicators was problem-
atic (four countries out of seven could collect data at individual level). 
Data sources and data collection principles are not clear and CQI 
are scattered, with insufficient scientific proof of particular indicator 
validity and reliability. Differences could also be related to country-
specific regulations and unfortunately may not always correlate with 
the good treatment quality results. As Europe is advancing towards 
harmonization in health care and as the necessity of maximizing the 
efficiency of health care spending is higher than ever, it seems neces-
sary to have appropriate instruments that permit comparisons across 
different models and systems of care. Large differences still exist not 
only in quality of PC across Europe but also in how it is measured.
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